The VICC.ORG Investigator Directory

Pierre Massion, M.D.

Ingram Professor of Cancer Research
Professor of Medicine (Allergy, Pulmonary, and Critical Care)
Professor of Cancer Biology
VICC Member
Pulmonary and Critical Care Medicine Doctor

Patient Contact Information:

615-936-2256

Healthcare Provider Contact Information:

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center PRB 640
2220 Pierce Avenue
Nashville, TN 37232
615-322-3412

Profile

Dr. Pierre Massion is the Ingram Professor of Cancer Research. He is Professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine and Professor of Cancer Biology at Vanderbilt Medical Center. Dr. Massion has worked in the field of lung cancer biology, early detection and therapeutics for 16 years. He is the director of the Thoracic Program at the Vanderbilt Ingram Cancer Center and thereby overseeing and fostering a rich environment to translate science from the program to trials in the cooperative groups. He has over 80 publications in the areas of lung cancer development, role of oncogenes in the progression of lung tumor cells and innovative strategies towards the development of molecular biomarkers for early detection of lung cancer and intermediate endpoint biomarkers of response to chemoprevention. He served as Chief of the Pulmonary and Critical Care Medicine section at the Nashville VA Medical Center between 2007-2012. He is certified by the American Board of Internal Medicine in Internal Medicine and in Pulmonary and Critical Care Medicine. He is the principal investigator of the Vanderbilt SPORE in lung cancer and of the Vanderbilt Clinical Validation Center sponsored by the EDRN to validate candidate biomarkers of lung cancer. He is also co-PI of two DoD grants, one of which offers lung cancer screening across 12 VA and military hospitals to validate candidate biomarkers of risk and of diagnosis for lung cancer. Dr. Massion has mentored over 19 postdoctoral fellows, 11 graduate students and 20 undergraduate students. He is committed to pursuing innovative strategies to deepen the understanding of lung cancer development and progression. His laboratory applies novel genomic and proteomic technologies to biological specimens to address questions related to the identification and validation of molecular determinants of disease diagnosis, progression, prognosis, and intermediate endpoint biomarkers of response to chemopreventive strategies. He is the PI of 6 active clinical studies - http://www.clinicaltrials.gov. He is the Chair of the Lung Cancer Cooperative group in the EDRN and the Chair of the Scientific Advisory Board of the largest non-profit lung cancer foundation LUNGevity. He is a contributing member to the National Comprehensive Cancer Network related Non-Small Cell Lung Cancer Guidelines committee.

Education

  • M.D. - Catholic University of Louvain
  • Fellowship - University of California San Francisco Medical Center
  • Internship - Saint Luc Hospital
  • Post Graduate Training - Catholic University of Louvain
  • Post Graduate Training - University of California San Francisco Medical Center
  • Residency - University of California San Francisco Medical Center

Research Specialty:

The laboratory of Dr. Massion emphasis is on lung tumorigenesis and on using genomic and proteomic approaches to identify molecular markers of lung neoplasia and to test those in multidisciplinary early detection strategies.

Research Description:

1. Role of chromosome 3q in lung cancer. Selection of candidate genes driving a genomic amplicon on Chromosome 3q. Focus on functional genomics for candidate driver genes on chromosome 3q such as p63 and PIK3CA. RO1 funded.

2. Proteomic approach to preinvasive lung cancer. Protein profiling of preinvasive lesions in bronchial biopsy and invasive lung cancer by MALDI MS; Identification of discriminatory proteins by LC-MSMS proteomics; Image analysis. funded by RO1 and SPORE in lung cancer.

3. Lung cancer biomarker discovery and validation. Identification of discriminatory proteins between lung cancer and controls after multidimensional mass spectrometry analysis of biological specimen and Phage-display recombinant antibody library (serum, plasma or pleural fluid). Funded by Vanderbilt SPORE in lung cancer, VA Merit review grant, ASCO research award and EDRN Clinical Validation Center (U01).

4. Inflammation and cancer. We are working on 3 proteins. PPAR delta in lung tumorigenesis (Pedchenko, 2008), Role of serum amyloid A in regulating apoptosis in lung cancer cells, and pIgR as a potential tumor suppressor gene in lung cancer (Polosukhin, 2007). Work supported by Damon Runyon Foundation and a Vanderbilt Discovery Grant.

Clincial Research Description:

Active Clinical Trials: Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease --This study is currently recruiting patients. http://clinicaltrials.gov/ct/gui/show/NCT00084409?order=2

Publications:

You do not have JavaScript enabled. This site works better with JavaScript turned on.